Enhanced In Vivo Immunogenicity Induced by an Antibody to the IL‐4 Receptor‐Associated gp200‐MR6 Molecule
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Four murine IgG1 monoclonal antibodies, each with specificity for a human tumour‐associated antigen, have been tested for their in vivo immunogenicity using a rabbit model. Surprisingly, one of these antibodies, MR6, was significantly more immunogenic than the remaining three reagents. This enhanced MR6 immunogenicity was not restricted to the immunoglobulin molecule itself, but also applied to a hapten (fluorescein isothiocyanate, FITC) when conjugated to the monoclonal antibody. In addition, the secondary immune response to an independent antigen, human haemoglobin, was higher when the antigen was administered simultaneously with MR6 than when co‐injected with an isotype‐matched control monoclonal antibody. The presence of the target antigen, gp200‐MR6, on both rabbit and human leucocytes and epithelium, and its known association with human IL‐4 function, raises the possibility that antibody MR6 may not only target immunogens to antigen‐presenting cells, but may also enhance the ability of these cells to present antigen to the immune system. Antibodies to the gp200‐MR6 may therefore find important clinical application as in vivo adjuvants.
